Company news
Starpharma Holdings Limited news in 2019
Starpharma Holdings Limited's news releases, calls and decks from 2019, newest first.
Commencement of phase 1 trial for AZD0466 utilising DEP
December 29, 2019
Starpharma receives $4.9M R&D tax incentive refund
December 15, 2019
DEP cabazitaxel progresses to phase 2 on positive results
December 9, 2019
AGM - Chairman address and CEO presentation
November 21, 2019
VivaGel condom receives regulatory approval in Europe
November 20, 2019
UK launch of VivaGel BV
November 12, 2019
DEP outperforms Gemzar in human pancreatic cancer model
October 30, 2019
FDA Authorises Clinical Trial with AstraZeneca DEP product
September 25, 2019
DEP irinotecan synergistic with Lynparza in refractory model
September 12, 2019
VivaGel BV regulatory approvals continue in Asia
September 2, 2019
Positive results with Targeted DEP using antibody fragment
August 29, 2019
Promising efficacy signals observed in ongoing DEP trials
August 27, 2019
First Asian Regulatory Approvals Received for VivaGel BV
August 14, 2019
Starpharma commences phase 1/2 DEP irinotecan trial
August 7, 2019
VivaGel BV launched in Europe
June 27, 2019
Starpharma signs second oncology agreement with AstraZeneca
June 2, 2019
DEP irinotecan combination outperforms in colon cancel model
May 24, 2019
First VivaGel BV launch globally in Australia by Aspen
April 16, 2019
Starpharma receives $4.0M R&D tax incentive refund
March 11, 2019
Interim Report and Half-Yearly Financial Results
February 26, 2019
Response to ASX Aware Letter
January 7, 2019
VivaGel condom receives final regulatory approval in Japan
January 1, 2019
Decks in 2019
- Shareholder Meeting (November 2019)
Shareholder meeting · 40 slides · Nov 21, 2019
- Goldman Sachs Tenth Annual Emerging Companies Conference 2019
Conference · 36 slides · Apr 3, 2019